Skip to main content
Premium Trial:

Request an Annual Quote

BU Takes 20% of Framingham Genomic Medicine

Premium

Boston University has taken a 20 percent stake in Framingham Genomic Medicine, a new company that will sell analyses of data from the university’s Framingham Heart Study.

 

Framingham Genomic Medicine is planning to hire a team of geneticists, biostatisticians, epidemiologists and bioinformatics specialists, who will be able to turn the genetic, clinical, and behavioral data collected from 10,000 participants over 52 years into research-quality information.

 

“The gist of this is that there is a real bottleneck in genomics--the availability of research--quality data,” said Fred Ledley, chief scientific officer at Framingham Genomic Medicine, who left his post as president and CEO of Variagenics last August.

 

“We will be putting 50,000 genetic markers on the samples in order to be able to do cross-correlations. The key is to build the database systems that allow the analyses to be performed.”

 

The company intends to buy tools as well as develop its own products that could then be commercialized.

 

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.